Karuna Therapeutics Inc

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Karuna Therapeutics reports positive trial results and strong financial outlook

Karuna Therapeutics is making significant progress in its key programs, with positive trial results and a focus on expanding its pipeline. Despite challenges in trial timelines and increased expenses, the company's strong financial position and strategic priorities position it well for future growth.

Karuna Therapeutics reports robust Q2 performance and eyes new indications

Karuna Therapeutics reported strong financials, progress on NDA submission, and ongoing Phase III programs.
The company's focus on cognitive benefits, broader efficacy, and potential new indications showcases strategic growth initiatives.
Challenges include competitive dynamics in Alzheimer's trials and uncertainties in the applicability of KarXT in certain patient populations.
Opportunities lie in exploring new indications, demonstrating cognitive benefits, and enhancing efficacy in mood and anxiety disorders.

Karuna Therapeutics excels in Q3, eyes global expansion for KarXT

Karuna Therapeutics demonstrated strong performance in Q3 with a focus on KarXT Phase III programs and NDA submission, supported by a healthy financial position.
Strategic strengths lie in maximizing KarXT value, positive payer interactions, and broad-based commercial strategies, while challenges include managing expenses and operational considerations.
Opportunities for growth include expanding the TRPC4/5 program, leveraging favorable mental health trends, and pursuing international market partnerships for KarXT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Karuna Therapeutics is a biopharmaceutical company that develops treatments for psychiatric and neurological conditions. Karuna Therapeutics creates drugs that can significantly improve the lives of people who suffer from neurological and psychiatric illnesses, with a particular focus on schizophrenia and the behavioral symptoms of Alzheimer's disease. The company is skilled in neuroscience and has creative ideas for finding and developing new drugs. Karuna Therapeutics is advancing a pipeline of innovative drugs since its inception with the aim of significantly improving the lives of people suffering from these difficult conditions.

Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.

Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update. “2023 was a landmark year for Karuna, marked by the FDA acceptance of our NDA for KarXT for the treatment of schizophrenia in adults, with.

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

Bristol-Myers

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeutics, Inc. (NasdaqGM: KRTX) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Karuna will receive $330.00 in cash for each share of Karuna that they own. KSF is seeking to determine whether this consideration and the process that led to it.

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

Alphabet

iShares Nasdaq Biotechnology ETF

iShares Russell 2000 ETF

Microsoft

NVIDIA

Novo Nordisk

Novartis

Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.

Bullish Continuation in '24? 3 Market Areas to Watch

AbbVie

Amgen

AstraZeneca

Cerevel Therapeutics Holdings Inc

Horizon Pharma

ImmunoGen

Mirati Therapeutics

Pfizer

Roche Holding AG

RayzeBio Inc

Seagen

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

Cramer names biopharma companies to watch as industry mergers start to pile up

Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.

Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers

Apple

Masimo

Nano Dimension

Stratasys

The holiday shopping season isn't over yet. A 3-D printing company and a major pharmaceuticals maker announced post-Christmas acquisitions Tuesday morning.

Nano Dimension Buys Stratasys, Bristol Myers's Shopping Spree, Apple Gets a ‘No'

Karuna Therapeutics Inc (NASDAQ: KRTX) ended nearly 50% up on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biopharmaceutical firm for $14 billion.

Bristol-Myers buying Karuna signals a biotech boom ahead: Jefferies

NEW YORK , Dec. 22, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Karuna Therapeutics, Inc. (NASDAQ: KRTX) and its board of directors concerning the proposed acquisition of the company by Bristol Myers Squibb (NYSE: BMY). Stockholders will receive $330.00 for each share of Karuna Therapeutics stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.

Shares of biopharmaceutical company Karuna Therapeutics skyrocketed more than 47% Friday morning after giant Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) announced a deal to acquire the company in a $14 billion cash deal.  The agreement valued Karuna at $330 per share.

Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B deal

NIKE

U.S. equities headed into the long holiday weekend with gains at midday, amid a broad-based rally fueled by enthusiasm over the possibility of several Fed interest rate cuts next year. The Dow, S&P 500, and Nasdaq were all up.

Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook

Karuna Therapeutics (KRTX) shares skyrocketed over 46% after Bristol Myers Squibb (BMY) said it would buy the biopharmaceutical firm for $14 billion to expand its neuroscience portfolio.

Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal

Dec 22 (Reuters) - Bristol Myers Squibb (BMY.N) on Friday agreed to buy Karuna Therapeutics (KRTX.O) for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as patents on its older therapies expire later this decade.

Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 bln

BioMarin Pharmaceutical

Blueprint Medicines

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Biotech stocks set for a rebound in 2024, analysts say

MILWAUKEE , Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Karuna (NASDAQ: KRTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol-Myers. Click here to learn how to join the https://www.ademilaw.com/case/karuna-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Karuna Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol-Myers

Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.

Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal

Carnival

Micron Technology

Paramount Global

Warner Bros Discovery Inc

Wells Fargo

Before U.S. markets opened on Friday, the Bureau of Economic Analysis released its personal income and spending report for November.

A Major Acquisition and Other News Ahead of the Holiday Weekend

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics, Inc., and (Nasdaq: KRTX) Bristol Myers Squibb (NYSE: BMY) announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on Friday, sending KRTX stock into the stratosphere.

Karuna Stock Soars On Bristol Myers' $14 Billion Takeover

Karuna's crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.

Bristol Myers to buy Karuna Therapeutics for $14B

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Karuna Therapeutics, Inc. (NASDAQ: KRTX) to Bristol Myers Squibb for $330.00 per share in cash is fair to Karuna shareholders. Halper Sadeh encourages Karuna shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Karu.

KRTX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Karuna Therapeutics, Inc. Is Fair to Shareholders

PRINCETON, N.J. & BOSTON--(BUSINESS WIRE)---- $KRTX--Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors. Ka.

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Karuna has an experimental schizophrenia drug called KarXT up for U.S. government approval.

Bristol Myers to Buys Karuna Therapeutics in $14 Billion Pharma Deal: Report

Shares of Karuna Therapeutics Inc. KRTX, +1.80% rocketed 33.8% into record territory in premarket trading Friday, after The Wall Street Journal reported that Bristol Myers Squibb Co. BMY, +0.59% has reached an agreement to buy the drug developer in a deal valued at $14 billion. Bristol Myers' stock slumped 2.7% ahead of the open.

Karuna Therapeutics' stock rockets into record territory after report Bristol Myers' $14 billion buyout agreement

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that results from the Phase 3 EMERGENT-2 trial of KarXT (xanomeline-trospium) in adults with schizophrenia were published in The Lancet. The manuscript shares KarXT data showcasing a clinically meaningful and statistically significant reduction in positive a.

Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

News for Karuna Therapeutics Inc Stock (KRTX)